15.de Fornasari ML, Dos Santos Sens YA. Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial[J]. J Ren Nutr. 2017;27(2):...
Stage 1: Kidney damage with normal or increased GFR (> 90 mL/min/1.73 m2) Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) Stage 3a: Moderate reduction in GFR (45-59 mL/min/1.73 m2) Stage 3b: Moderate reduction in GFR (30-44 mL/min/1.73 m2) Stage 4: Severe redu...
We evaluated symptom burden and its impact on quality of life in patients with moderate to advanced CKD.Method 4423 patients with CKD Stage 3 to 5 from Brazil (N=548), France (N=2691), and the US (N=1184) enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CK...
Between February 2008 and March 2010, 90 patients with stage 3 to 4 CKD underwent an exercise stress echocardiogram, and 83 who passed this screening were assigned to 12 months of standard care (control) or lifestyle intervention. The latter intervention included multidisciplinary care at a CKD c...
stage 1 CKD kidney damage with normal or increased GFRmore than 90 stage 2 CKD mild reduction in GFR60-89 stage 3a CKD moderate reduction on GFR 45-59 stage 3b CKD moderate reduction in GFR 30-44 stage 4 CKD severe reduction in GFR15-29 stage 5 CKD kidney failureless than 15 or dial...
stage 1-- GFR > 90 stage 2-- GFR 60-89 (mild) stage 3-- GFR 30-59 (moderate) stage 4-- GFR 15-29 (severe) stage 5-- GFR < 15 (ESRD) what causes CKD? aging, obesity, DM, HTN what are theclinical manifestationsof CKD in theurinary system?
35 Although informative for moderate (stage 3) CKD, many large trials and meta-analyses to date characterize CKD as a homogeneous group of patients with any GFR < 60 mL/min/1.73 m2 and therefore conclusions regarding NSAID risk based on these studies cannot be applied to patients with more ...
The CKD WIT study was a 1-year RCT (not double-blinded) of 631 Canadian patients with stage 3 CKD (data for 590 patients were available for final analysis). The patients who were enrolled in the intervention arm were encouraged by the research staff to increase their water intake by at ...
CKD指南：PCP指南，用于CKD检测和延缓进展说明书
Kerendia® (finerenone) is an FDA approved treatment for adult patients with CKD associated with T2D. See Safety and Full Prescribing Info.